Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour ce ...
Angle PLC 29 January 2025 For immediate release 29 January 2025 ANGLE plc ("the Company") NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing...
Angle PLC on Thursday said it expected losses to have narrowed in 2024, but its share price suggested lingering marke ...
Angle PLC 23 January 2025 For immediate release 23 January 2025 ANGLE plc ("the Company") TRADING UPDATE Revenue for 2024 expected to be up 31% Lower cost base going into 2025 with a...
Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patien ...
Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung canc ...
The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported b ...
Angle PLC 26 September 2024 For Immediate Release 26 September 2024 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY...
Angle PLC 23 September 2024 For immediate release 23 September 2024 ANGLE plc ("the Company") ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE Option for...
ford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a ...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.5 | 20 | 12.5 | 16.25 | 11.25 | 2836477 | 13.04377168 | DE |
4 | 4.75 | 46.3414634146 | 10.25 | 16.25 | 10.25 | 1276894 | 12.435787 | DE |
12 | 7 | 87.5 | 8 | 16.25 | 7.75 | 1356045 | 11.08314458 | DE |
26 | 0.375 | 2.5641025641 | 14.625 | 16.25 | 7.25 | 1122995 | 10.73600186 | DE |
52 | -2.5 | -14.2857142857 | 17.5 | 25 | 7.25 | 1393864 | 14.08708615 | DE |
156 | -101 | -87.0689655172 | 116 | 163.5 | 7.25 | 1572702 | 29.90909036 | DE |
260 | -58 | -79.4520547945 | 73 | 163.5 | 7.25 | 1231334 | 42.13662436 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관